Cargando…

Evaluation of laboratory values affecting mortality of end-stage renal disease patients: a competing risks approach

BACKGROUND: Chronic Kidney Disease (CKD) is a prevalent and life-threatening situation recognized as an emerging health issue. The present study aimed to evaluate the effect of demographic and laboratory parameters on the survival of patients with End-Stage Renal Disease (ESRD) in a hemodialysis (HD...

Descripción completa

Detalles Bibliográficos
Autores principales: Malek, Rayka, Baghestani, Ahmadreza, Rashid-Farokhi, Farin, Shafaghi, Shadi, Minoo, Farzanehsadat, Eghbali, Foolad, Chandra, Navin, Shafaghi, Masoud, Bonyadi, Kaveh, Hosseini-Baharanchi, Fatemeh Sadat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353130/
https://www.ncbi.nlm.nih.gov/pubmed/37464291
http://dx.doi.org/10.1186/s12882-023-03234-x
_version_ 1785074656618741760
author Malek, Rayka
Baghestani, Ahmadreza
Rashid-Farokhi, Farin
Shafaghi, Shadi
Minoo, Farzanehsadat
Eghbali, Foolad
Chandra, Navin
Shafaghi, Masoud
Bonyadi, Kaveh
Hosseini-Baharanchi, Fatemeh Sadat
author_facet Malek, Rayka
Baghestani, Ahmadreza
Rashid-Farokhi, Farin
Shafaghi, Shadi
Minoo, Farzanehsadat
Eghbali, Foolad
Chandra, Navin
Shafaghi, Masoud
Bonyadi, Kaveh
Hosseini-Baharanchi, Fatemeh Sadat
author_sort Malek, Rayka
collection PubMed
description BACKGROUND: Chronic Kidney Disease (CKD) is a prevalent and life-threatening situation recognized as an emerging health issue. The present study aimed to evaluate the effect of demographic and laboratory parameters on the survival of patients with End-Stage Renal Disease (ESRD) in a hemodialysis (HD) center in Iran. MATERIALS AND METHODS: This study was conducted on patients receiving chronic HD in Iran Helal Pharmaceutical and Clinical Complex between 2014 and 2018. The survival time was considered as the time interval between HD initiation and death. Receiving kidney transplantation was regarded as a competing risk, and an improper form of two-parameter Weibull distribution was utilized to simultaneously model the time to both death and renal transplantation. The Bayesian approach was conducted for parameters estimation. RESULTS: Overall, 29 (26.6%) patients expired, and 19 (17.4%) received kidney transplants. The male gender was related to poor survival, having nearly 4.6 folds higher hazard of mortality (90% HPD region: 1.36–15.49). Moreover, Serum calcium levels [Formula: see text]9.5 mg/dL (adjusted Sub-hazard ratio (S-HR)=2.33, 90% HPD region: 1.05–5.32) and intact parathyroid hormone (iPTH) [Formula: see text]150 pg/mL (adjusted S-HR = 2.56, 90% HPD region: 1.09–6.15) were associated with an elevated hazard of mortality. The cumulative incidence function (CIF) for transplantation was greater than death in the first two years of the study. Subsequently, the CIF for death exceeded transplantation in the following two years. The 4-year cumulative incidence of death and kidney transplantation was 63.7% and 36.3%, respectively. CONCLUSION: Male gender, hypercalcemia, and hypoparathyroidism were associated with worse outcomes. Correcting mentioned laboratory parameters may improve patients’ survival in the HD population.
format Online
Article
Text
id pubmed-10353130
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103531302023-07-19 Evaluation of laboratory values affecting mortality of end-stage renal disease patients: a competing risks approach Malek, Rayka Baghestani, Ahmadreza Rashid-Farokhi, Farin Shafaghi, Shadi Minoo, Farzanehsadat Eghbali, Foolad Chandra, Navin Shafaghi, Masoud Bonyadi, Kaveh Hosseini-Baharanchi, Fatemeh Sadat BMC Nephrol Research BACKGROUND: Chronic Kidney Disease (CKD) is a prevalent and life-threatening situation recognized as an emerging health issue. The present study aimed to evaluate the effect of demographic and laboratory parameters on the survival of patients with End-Stage Renal Disease (ESRD) in a hemodialysis (HD) center in Iran. MATERIALS AND METHODS: This study was conducted on patients receiving chronic HD in Iran Helal Pharmaceutical and Clinical Complex between 2014 and 2018. The survival time was considered as the time interval between HD initiation and death. Receiving kidney transplantation was regarded as a competing risk, and an improper form of two-parameter Weibull distribution was utilized to simultaneously model the time to both death and renal transplantation. The Bayesian approach was conducted for parameters estimation. RESULTS: Overall, 29 (26.6%) patients expired, and 19 (17.4%) received kidney transplants. The male gender was related to poor survival, having nearly 4.6 folds higher hazard of mortality (90% HPD region: 1.36–15.49). Moreover, Serum calcium levels [Formula: see text]9.5 mg/dL (adjusted Sub-hazard ratio (S-HR)=2.33, 90% HPD region: 1.05–5.32) and intact parathyroid hormone (iPTH) [Formula: see text]150 pg/mL (adjusted S-HR = 2.56, 90% HPD region: 1.09–6.15) were associated with an elevated hazard of mortality. The cumulative incidence function (CIF) for transplantation was greater than death in the first two years of the study. Subsequently, the CIF for death exceeded transplantation in the following two years. The 4-year cumulative incidence of death and kidney transplantation was 63.7% and 36.3%, respectively. CONCLUSION: Male gender, hypercalcemia, and hypoparathyroidism were associated with worse outcomes. Correcting mentioned laboratory parameters may improve patients’ survival in the HD population. BioMed Central 2023-07-18 /pmc/articles/PMC10353130/ /pubmed/37464291 http://dx.doi.org/10.1186/s12882-023-03234-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Malek, Rayka
Baghestani, Ahmadreza
Rashid-Farokhi, Farin
Shafaghi, Shadi
Minoo, Farzanehsadat
Eghbali, Foolad
Chandra, Navin
Shafaghi, Masoud
Bonyadi, Kaveh
Hosseini-Baharanchi, Fatemeh Sadat
Evaluation of laboratory values affecting mortality of end-stage renal disease patients: a competing risks approach
title Evaluation of laboratory values affecting mortality of end-stage renal disease patients: a competing risks approach
title_full Evaluation of laboratory values affecting mortality of end-stage renal disease patients: a competing risks approach
title_fullStr Evaluation of laboratory values affecting mortality of end-stage renal disease patients: a competing risks approach
title_full_unstemmed Evaluation of laboratory values affecting mortality of end-stage renal disease patients: a competing risks approach
title_short Evaluation of laboratory values affecting mortality of end-stage renal disease patients: a competing risks approach
title_sort evaluation of laboratory values affecting mortality of end-stage renal disease patients: a competing risks approach
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353130/
https://www.ncbi.nlm.nih.gov/pubmed/37464291
http://dx.doi.org/10.1186/s12882-023-03234-x
work_keys_str_mv AT malekrayka evaluationoflaboratoryvaluesaffectingmortalityofendstagerenaldiseasepatientsacompetingrisksapproach
AT baghestaniahmadreza evaluationoflaboratoryvaluesaffectingmortalityofendstagerenaldiseasepatientsacompetingrisksapproach
AT rashidfarokhifarin evaluationoflaboratoryvaluesaffectingmortalityofendstagerenaldiseasepatientsacompetingrisksapproach
AT shafaghishadi evaluationoflaboratoryvaluesaffectingmortalityofendstagerenaldiseasepatientsacompetingrisksapproach
AT minoofarzanehsadat evaluationoflaboratoryvaluesaffectingmortalityofendstagerenaldiseasepatientsacompetingrisksapproach
AT eghbalifoolad evaluationoflaboratoryvaluesaffectingmortalityofendstagerenaldiseasepatientsacompetingrisksapproach
AT chandranavin evaluationoflaboratoryvaluesaffectingmortalityofendstagerenaldiseasepatientsacompetingrisksapproach
AT shafaghimasoud evaluationoflaboratoryvaluesaffectingmortalityofendstagerenaldiseasepatientsacompetingrisksapproach
AT bonyadikaveh evaluationoflaboratoryvaluesaffectingmortalityofendstagerenaldiseasepatientsacompetingrisksapproach
AT hosseinibaharanchifatemehsadat evaluationoflaboratoryvaluesaffectingmortalityofendstagerenaldiseasepatientsacompetingrisksapproach